Full-Time

Senior Continuous Improvement Engineer

Hematology

Bio-Techne

Bio-Techne

1,001-5,000 employees

Purified proteins and reagents supplier

Compensation Overview

$87.6k - $144k/yr

No H1B Sponsorship

Minneapolis, MN, USA

In Person

Must work on-site at the Minneapolis location; remote work is not available.

Bachelor's, Master's

Category
Manufacturing & Process Engineering
Required Skills
Power BI
Minitab
Microsoft Office
ERP
Supply Chain Management
Six Sigma
Financial analysis
Quality Assurance (QA)
Excel/Numbers/Sheets

Get referred to Bio-Techne

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Engineering, Operations, or a related field.
  • At least 7 years of experience in continuous improvement, manufacturing, or operations.
  • Strong analytical and problem-solving skills.
  • Proficiency in Microsoft Office and basic data visualization tools such as Excel and Power BI.
  • Executive-level communication and influence.
  • Expertise in Lean, Six Sigma, and change management.
  • Strong business acumen and financial analysis skills.
  • Experience with enterprise resource planning, manufacturing execution systems, and digital continuous-improvement tools.
  • Proficiency with statistical process control software such as Minitab or JMP.
  • Ability to work independently on assigned tasks with general guidance.
  • Experience participating in cost savings, productivity improvement, or automation initiatives.
  • Basic knowledge of manufacturing equipment, process automation, programmable logic controller-controlled systems, or digital manufacturing technologies.
  • Ability to run Visual Factory systems and lead effective Gemba walks.
  • Ability to support multiple improvement and automation projects simultaneously in a fast-paced manufacturing environment.
  • Ability to work collaboratively in a team environment and take direction from senior team members.
  • Commitment to quality, safety, and regulatory compliance.
  • Ability to work on-site at the Minneapolis location.
  • Ability to work standard business-operation hours, sit or stand for extended periods, and occasionally lift materials up to 25 pounds.
  • Ability to use computers and office equipment.
Responsibilities
  • Assist in identifying process-improvement opportunities within hematology reagents manufacturing through analytical evaluation.
  • Identify, prioritize, and support cost-improvement initiatives that improve productivity, reduce waste, optimize resource utilization, and enhance operational efficiency.
  • Own and run Visual Factory management systems and lead Gemba walks to observe processes, engage frontline teams, and identify improvement opportunities.
  • Support data collection, analysis, and reporting using SmartSheets and Power BI.
  • Participate in Lean, Six Sigma, and Kaizen projects under the guidance of senior continuous-improvement professionals.
  • Support or lead manufacturing automation projects, including process automation, equipment improvements, digital-transformation initiatives, and implementation of new technologies.
  • Evaluate automation opportunities and develop business cases supporting productivity improvements, capacity expansion, quality enhancement, and cost reduction.
  • Create process flowcharts, standard operating procedures, and training materials to support standardized processes.
  • Collaborate with Quality Assurance, Quality Control, Engineering, Maintenance, Supply Chain, and production teams to facilitate continuous-improvement efforts and communicate project insights.
  • Monitor key performance indicators and provide regular updates to the continuous-improvement team and leadership.
  • Learn and apply artificial-intelligence-assisted analytics to identify trends and improvement opportunities.
  • Maintain compliance with regulatory and quality requirements by integrating continuous-improvement activities with quality and safety standards.
  • Contribute to fostering a culture of continuous improvement throughout the manufacturing department.
Desired Qualifications
  • Exposure to regulated manufacturing environments, pharmaceuticals, biotechnology, medical devices, or diagnostic manufacturing.
  • Eagerness to develop skills in process-improvement methodologies, project management, and automation technologies.

Bio-Techne makes and sells life-science tools such as purified proteins, cytokines, growth factors, antibodies, immunoassays, and reagent solutions, along with ProteinSimple analytics and cell/gene therapy workflow technologies. Researchers use these products to produce, analyze, and quantify biomolecules and to carry out assays and workflow steps in cancer, immunology, and regenerative medicine. The company differentiates itself with a broad, integrated catalog and end-to-end support—from raw proteins to analytical solutions—delivered to a global customer base. Its goal is to be a leading provider of life-science tools that speed up discovery and development in healthcare and biology.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Minneapolis, Minnesota

Founded

1981

Get referred to Bio-Techne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's $11.3 billion cash deal values Bio-Techne at $73 per share.
  • Q4 fiscal 2026 revenue reached $321.2 million, with 3% organic growth and 65.8% gross margin.
  • SBTi validated a 70% Scope 1-2 reduction target by fiscal 2031.

What critics are saying

  • U.S. academic funding cuts already hurt Q3 2026 sales and buying intent.
  • Merck's 2026 acquisition faces shareholder litigation, regulatory review, and closing risk into early 2027.
  • Diagnostics leader Matt McManus exited in March 2026, signaling integration and retention strain.

What makes Bio-Techne unique

  • Bio-Techne owns R&D Systems, ProteinSimple, and RNAscope across discovery-to-manufacturing workflows.
  • Its 6,000-protein catalog and 425,000-antibody base create switching costs for researchers.
  • AI-Engineered Designer Proteins target cell therapy reproducibility, a niche with premium pricing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Short-term Disability

Long-term Disability

Pet Insurance

Legal Services

401(k) Company Match

Company Equity

Professional Development Budget

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

Unlimited Paid Time Off

Hybrid Work Options

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

1%
PR Newswire
Sep 1st, 2026
Bio-Techne cuts emissions 49%, gets SBTi validation for 70% reduction target by 2031

Bio-Techne has achieved validation of its greenhouse gas reduction targets from the Science Based Targets initiative. The life sciences company aims to cut absolute Scope 1 and 2 emissions by 70% by fiscal 2031 from a fiscal 2025 baseline. In fiscal 2026, Bio-Techne reduced market-based Scope 1 and 2 emissions by 49% year-over-year. The company now sources 51% of its electricity from renewable sources after transitioning its Minneapolis headquarters and St Paul GMP facility to renewable power. Bio-Techne also committed that 81% of suppliers by spend will have science-based targets by fiscal 2030. The company completed its first comprehensive Scope 3 emissions inventory during the year. The Minnesota-based company generated over $1.2 billion in net sales in fiscal 2026.

Yahoo Finance
Aug 31st, 2026
Bio-Techne beats Q2 revenue expectations by 2% with $321M in sales

Bio-Techne reported Q2 revenues of $321.2 million, up 1.3% year on year and exceeding analyst expectations by 2%. The life sciences company, which manufactures specialised reagents, instruments, and services for researchers, delivered a strong quarter with solid organic revenue performance. The research tools and consumables sector faces both opportunities and challenges. Whilst emerging fields like synthetic biology and personalised medicine drive demand, companies must navigate high R&D costs, pricing pressures from budget-conscious institutions, and vulnerability to research funding fluctuations. The 10 research tools and consumables stocks tracked collectively beat revenue estimates by 1.7% in Q2. Share prices have risen 6.3% on average since the latest earnings results.

Yahoo Finance
Aug 13th, 2026
Bio-Techne Q4 revenues hit $321.2M, up 3% organically, stock edges up

Bio-Techne Corporation reported adjusted earnings per share of 52 cents for the fourth quarter of fiscal 2026, meeting the Zacks Consensus Estimate despite a 1.9% year-over-year decline. GAAP EPS was 35 cents, compared to a loss of 11 cents in the prior-year quarter. Fourth-quarter net sales reached $321.2 million, up 1% year over year on a reported basis and 3% organically, surpassing the consensus estimate by 1.26%. Full-year revenues were $1.22 billion, remaining flat from fiscal 2025. The Protein Sciences segment generated revenues of $231.2 million, up 2% year over year. Diagnostics and Spatial Biology revenues remained roughly flat at $90.1 million. Gross margin expanded 310 basis points to 65.8%. The company generated operating income of $74.3 million, compared to an operating loss of $23.9 million in the year-ago quarter. Following the announcement, shares edged up 0.1% to close at $72.23.

Yahoo Finance
Jul 16th, 2026
Bio-Techne misses Q1 revenue estimates as research tools sector shows mixed results

Bio-Techne reported mixed Q1 results with revenues of $311.4 million, down 1.5% year on year and falling short of analysts' expectations by 1.6%. The company, which manufactures specialised reagents, instruments, and services for researchers, saw its EPS meet analysts' estimates whilst organic revenue missed expectations. The research tools and consumables sector overall performed better, with the 10 tracked stocks beating revenue consensus estimates by 1.3% as a group. Next quarter's revenue guidance came in 2% above expectations. Share prices in the sector have risen 21.8% on average since the latest earnings results. The sector benefits from recurring revenue streams and customer loyalty but faces challenges including R&D investment requirements and vulnerability to research funding fluctuations.

AZoM.com Limited
Jul 8th, 2026
Bio-Techne launches expanded R&D Systems AI-Engineered Designer Protein portfolio.

Bio-Techne launches expanded R&D Systems AI-Engineered Designer Protein portfolio. Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems(TM) AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents. By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes. A guide to advancing biotherapeutic research eBook. Welcome to your essential guide to advancing biotherapeutic research. These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing. Early adopters of R&D Systems AI-Engineered Designer Proteins are already seeing measurable gains in cell expansion and overall workflow performance across demanding applications: "Many patient-derived Tumor-Infiltrating Lymphocytes (TIL) samples fail during initial outgrowth due to insufficient cell expansion," said Dr Branden Moriarity, Associate Professor in the Division of Pediatric Hematology/Oncology, University of Minnesota. "IL-2 Heat Stable Agonist Protein provides a promising proliferation advantage to TIL samples and also provides clear operational advantages that would reduce the cost of goods for TIL therapies." This real-world feedback underscores the broader potential of the R&D Systems AI-Engineered Designer Protein platform. With its latest expansion to include additional cytokines and growth factors, the platform is designed to enable more consistent, scalable, and cost-efficient advanced cell culture workflows. As cell therapy advances from early research into clinical and commercial manufacturing, achieving consistency, robustness, and scalability across increasingly complex workflows is critical, Its AI-Engineered Designer Proteins are designed to overcome these challenges by delivering enhanced stability, activity, and performance-enabling more reproducible results and supporting seamless scale-up from discovery through production." Will Geist, President, Protein Science Segment, Bio-Techne The newly launched proteins include: * FGF-4 Heat Stable - Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity. * FGF-7 Heat Stable - Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures. * FGF-8b Heat Stable - Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical. * IL-3 Heat Stable - Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture. * IL-15 Hyperactive - Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital. The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success. Be the first to rate this article